Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when DNTH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsDianthus reports 75% CIDP interim response rate, initiates Phase 3 gMG trial, unveils DNTH312
Filed August 4, 2026 · Period ending August 4, 2026 · ~1 min read
Key Changes
-
high
Phase 3 CIDP trial showed 75% response rate in first 40 patients, exceeding 50% target, with no serious infections, drug-induced lupus, or safety discontinuations; Part B guidance expected by year-end 2026.
Exhibit 99.1 view on EDGAR → -
high
Exhibit 99.1 view on EDGAR →
-
high
Announced DNTH312, a first-in-class bifunctional fusion protein combining claseprubart and TACI to inhibit aC1s and BAFF/APRIL pathways; preclinical data showed comparable potency to claseprubart with Phase 1 readiness targeted by year-end 2027.
Exhibit 99.1 view on EDGAR → -
high
Exhibit 99.1 view on EDGAR →
-
medium
Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy completed enrollment with 46 patients versus 36 target; top-line results on track for December 2026.
Exhibit 99.1 view on EDGAR →
Summary
Dianthus reported strong clinical progress across its neuromuscular pipeline, headlined by a 75% interim response rate in the first 40 patients completing Part A of the Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
The result exceeded the company's 50% target based on prior aC1s inhibition data and was accompanied by a clean safety profile—no serious infections, no drug-induced lupus symptoms, and no safety-related discontinuations. Separately, Dianthus unveiled DNTH312, a first-in-class bifunctional fusion protein combining claseprubart's aC1s inhibition with TACI-mediated BAFF/APRIL inhibition. Preclinical data showed comparable potency to claseprubart and similar immunoglobulin reductions to povetacicept in non-human primates, with a 22-day half-life in NHPs. The company aims to have DNTH312 Phase 1 ready by year-end 2027, expanding its autoimmune disease pipeline. Financially, Dianthus reported a Q2 2026 net loss of $50.2 million ($0.90 per share), up from $31.6 million ($0.88 per share) in Q2 2025, driven by R&D expenses of $48.7 million to support advancing Phase 2 and Phase 3 programs. The company holds approximately $1.2 billion in cash, cash equivalents, and investments, expected to fund operations into 2030. The Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy completed enrollment with 46 patients versus the original 36 target, with top-line results on track for December 2026.
Section-by-Section Diff
Event · Exhibit 99.1
Dianthus reported Q2 2026 results, announced Phase 3 gMG trial initiation, 75% CIDP interim response rate, and unveiled DNTH312 bifunctional fusion protein.
Added in current filing · view on EDGAR → · paraphrased
DNTH312 is an internally developed, investigational, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL. By targeting two validated pathways with complementary disease modifying mechanisms, DNTH312 expands Dianthus' leadership position in autoimmune diseases with its potential for best-in-disease efficacy by targeting deeper responses and broader symptom control, while also addressing larger patient populations. DNTH312 demonstrated comparable in vitro potency and aC1s inhibition to claseprubart across several functional assays of Classical Pathway inhibition and a similar depth of IgM, IgA, and IgG reductions vs. published values for povetacicept following a single dose in non-human primates (NHPs). Additionally, DNTH312 is enhanced with YTE half-life extension technology, and has a similar NHP half-life (22 days) to claseprubart, which has an approximately 60-day half-life in humans. DNTH312 aims to be Phase 1 ready by YE'27.
Dianthus announced DNTH312, an internally developed, first-in-class bifunctional fusion protein combining claseprubart (aC1s inhibitor) and TACI (BAFF/APRIL inhibitor) to target two validated pathways in autoimmune diseases. Preclinical data showed comparable potency to claseprubart and similar immunoglobulin reductions to povetacicept in non-human primates, with a 22-day half-life in NHPs (claseprubart has approximately 60-day half-life in humans). The company aims to have DNTH312 Phase 1 ready by year-end 2027.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 5, 2026 · How we verify